In meta-analysis of 10 clinical trials in which NSCLC was treated with paclitaxel and/or vinorelbine, Zhang et al. [9] demonstrated a correlation between low expression of mRNA for the TUBB3 gene and favorable outcomes – in the group of patients with low expression percentage of objective response was higher, and median survival longer. Here, TUBB3 is linked to non-small cell lung carcinoma.